CLINICAL TRIALS AND OBSERVATIONS Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
نویسندگان
چکیده
1Department of Lymphoma and Myeloma, M. D. Anderson Cancer Center, Houston, TX; 2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; 3Department of Medicine, Princess Margaret Hospital, Toronto, ON; 4Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 5Division of Hematology, Centre Hospitalier Université de Purpan, Toulouse, France; 6Department of Malignant Hematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia; 7Mayo Clinic Cancer Center, Rochester, MN; and 8Celgene, Summit, NJ
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA; 2Myeloma Program, Karmanos Cancer Institute, Detroit, MI; 3University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and 5College of ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
The objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/ dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair anal...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
1Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg and Early Clinical Development Unit of Comprehensive Cancer Center Mainfranken (CCCM), Wuerzburg; 2Department of Hematology/Oncology, HELIOS Klinikum Berlin Buch, Berlin; 3Department of Internal Medicine III, University Hospital, Ulm; 4Medizinische Klinik und Poliklinik I, Universität...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/ Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12, and 17 to 20 of each cycle. Objective response was defined as a decrease in serum monoclonal pr...
متن کامل